SipNose

Company Overview

Snapshot

Founded in November 2011 by Daniel Shahaf, SipNose operates with 1–10 employees. The company was acquired by Aptar Pharma in October 2024.

Business overview

SipNose is a Health Tech & Life Sciences company specializing in nose-to-brain medical applications. The company develops an intranasal drug-delivery platform designed for local, systemic, and central nervous system indications. Its noninvasive devices aim to ensure accurate dose delivery via the nasal cavity, improving drug absorption into the olfactory bulb and brain for various drug molecules. SipNose serves the pharmaceuticals and medical devices sectors, focusing on enhancing efficacy, patient compliance, and safety in drug administration.

Strategic signal

SipNose's acquisition by Aptar Pharma in October 2024 signals a strategic validation of its intranasal drug-delivery platform. This move by a multinational entity like Aptar Pharma suggests a growing industry interest in advanced drug delivery systems, particularly those targeting the brain more efficiently. For investors, this indicates a potential for consolidation and strategic exits within the specialized drug delivery technology market.

Company Intelligence Q&A

What is SipNose's primary focus?

SipNose focuses on nose-to-brain medical applications, developing an intranasal drug-delivery platform for local, systemic, and central nervous system indications.

When was SipNose founded?

SipNose was founded in November 2011.

Who is a co-founder of SipNose?

Daniel Shahaf is a co-founder and CTO of SipNose.

What was a key partnership for SipNose in June 2021?

In June 2021, SipNose Ltd. and Noveome Biotherapeutics, Inc. announced a commercial license agreement for the SipNose Cribriform Targeted Device.